logo IDIBELL
Català  |   Castellano  |   English
Search
The InstituteResearchWhat's onCalendarPlatformsJob offersTools
 

News

boto imprimir
Date: 26/02/2013

IDIBELL Researchers explain the latest advances in research on rare diseases

February 28th, World Rare Diseases Day


February 28 is the World Rare Diseases Day. In order to increase transparency about these diseases that affect more than 350 million people worldwide, the Bellvitge Biomedical Research Institute (IDIBELL) and the University of Barcelona have organized a panel discussion on the current state of research on rare diseases.

 

The conference has been given by Virginia Nunes, UB-IDIBELL researcher, specialist in Wolfram syndrome; Aurora Pujol, IDIBELL and ICREA researcher, specialist in adrenoleukodystrophies; Teresa Casals, IDIBELL researcher, specialist in cystic fibrosis, and Maria Berdasco, IDIBELL researcher, specialist in Sotos syndrome. The session has had the collaboration of the Catalan Association of Scientific Communication (ACCC).

 

This initiative aims to bring to society the research results done in rare diseases at UB and IDIBELL to find new strategies for treatment and prevention.

 

Genetics of rare diseases

 

80% of rare diseases are hereditary. In this case it is essential to know the genetics of disease. During two decades Virginia Nunes has been studied the molecular genetics of Wolfram syndrome, a rare progressive recessive and neurodegenerative disease. It is characterized by the onset of different disorders in patient's life: diabetes, optic atrophy, diabetes insipidus, deafness and other neurological and nephrology disorders. The mutations in WFS1 gene are responsible for the disease.

 

From laboratory to clinic

 

IDIBELL researcher Aurora Pujol leads the research group of Neurometabolic Diseases. Her recent research focuses on the X-linked adrenoleukodystrophy, a rare neurodegenerative disease that affects one in 17,000 people. The researcher have shown that oxidative stress is a major factor in this disease, and have tested in mice a cocktail of antioxidants that remit the locomotor system symptoms. Currently this cocktail is being tested in a clinical trial with 13 patients.

 

The most common rare disease

 

Cystic Fibrosis occurs in one in 2,000 to 5,000 people from the Caucasian population and mainly affects the lungs but also the liver, pancreas and intestine. Currently, no curative treatment is available, but there are therapies to improve the symptoms and the quality of life of patients. Basic research is needed to understand the pathophysiology and the genetic mutations that lead to disease. IDIBELL researcher Teresa Casals investigates new methods of diagnosis to know the effects of mutations in search of new biomarkers that may be useful as therapeutic targets to combat the disease.

 

Epigenetic approach

 

Sotos syndrome is a rare condition characterized by excessive growth of the body during early life with macrocephaly and motor and learning difficulties and is caused by mutations that inactivate the gene NSD1. IDIBELL researcher María Berdasco studies the changes that this mutation causes in the epigenome, ie chemical brands that carry genes, and also the connections between disease and a greater tumour willingness in patients.

 

New initiatives

 

During the conference, Lurdes Jordi, Director of the Valorisation Area of the Bosch i Gimpera Foundation has presented a new program launched with the objective of obtaining resources for research in rare disease at the University of Barcelona and its linked research centres.





Share/Bookmark
 
© 2014 Institut d'Investigació Biomèdica de Bellvitge



Results by pageInitial date
Select date
TitleFinal date
Select date
Search


Your password is about to expire. Please, write in a new password to continue

Remember this password allows you to access to all IDIBELL’s web applications

New password:
Confirm new password:

Accept



Your password is about to expire. Please, write in a new password to continue

Remember this password allows you to access to all IDIBELL’s web applications

New password:
Confirm new password:

Accept


Cancell

Passwords doesn’t match
The password must have at least 6 characters
The new password can not contain special characters
User register

Name
Surname
Second Surname
E-mail
User
Password
Language


Accept


Cancell




You have not yet answered the Human Resources Strategy for Research survey. It will not take you more than five minutes. Your opinion is very important to improve IDIBELL.

Do you want to complete the survey now?

Yes

No




Further personal and contact information is needed to maintain IDIBELL databases.

Do you wish to fill the form now?

Yes

No